Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Veracyte Inc (NASDAQ:VCYT)

5.60
Delayed Data
As of Feb 12
 +0.27 / +5.07%
Today’s Change
4.59
Today|||52-Week Range
12.47
-22.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$154.9M

Company Description

Veracyte, Inc. is a molecular diagnostics company. The company discovers, develops and commercializes molecular diagnostic solutions that enable physicians to make more informed treatment decisions early. Its first commercial solution is Afirma Thyroid FNA Analysis, which specializes in cytopathology assessment with the afirma gene expression classifier, a genomic test that clarifies inconclusive thyroid nodule results as benign or suspicious for cancer. The company was founded by Bonnie H. Anderson and Doug Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Contact Information

Veracyte, Inc.
7000 Shoreline Court
South San Francisco California 94080
P:(650) 243-6300
Investor Relations:
(650) 380-4413

Employees

Shareholders

Individual stakeholders50.45%
Other institutional26.46%
Mutual fund holders16.72%

Top Executives

Bonnie H. AndersonPresident, Chief Executive Officer & Director
Christopher M. HallChief Operating Officer
Shelly D. GuyerChief Financial Officer
Giulia C. KennedyChief Scientific Officer
Neil M. BarthChief Medical Officer